All In Biotech

Drug Trial Radar · NCT03676751

MORDOR II Burkina Faso: Longitudinal Trial

Gut and Azithromycin Mechanisms in Infants and Neonates

Last checked: Nov 20, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Oct 10, 2019

Primary completion

Jul 6, 2020

Study completion Jul 6, 2020

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Centre de Recherche en Sante de Nouna, Burkina Faso; Bill and Melinda Gates Foundation
First posted
Sep 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 8 days, up to 59 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Globally, childhood mortality has shown a promising downward trend in recent years, however, many sub-Saharan countries still have relatively high child mortality rates. In previous studies within Niger, Tanzania, and Malawi, mass azithromycin treatment to children aged 1-59 months old effectively reduced all-cause childhood mortality. A similar study will be conducted in Burkina Faso to replicate the results of mass azithromycin treatment. The investigators propose an individually randomized placebo-controlled trial alongside the MORDOR II Burkina Faso trial to evaluate the effect of a single dose of azithromycin (20 mg/kg) on potential mediators of the effect of azithromycin on all-cause mortality. Many questions surround the mechanism behind azithromycin's effect on reducing childhood mortality. Further questions exist regarding antibiotic resistance and how mass antibiotic administration can impact intestinal microflora. The goal of this study is to demonstrate the changes in the gut microbiome after antibiotic administration and to measure the growth of children after receiving a single dose of azithromycin. Additionally we will measure resistance markers, inflammatory markers, and IgA-bound bacteria. We hypothesize that a single dose of azithromycin will lead to a significant increase in child growth and that the gut microbiome will be significantly different in children who received azithromycin compared to those who received placebo. Objectives: 1. . To determine the effect of a single dose of azithromycin for children aged 8 days-59 months on longitudinal changes in the intestinal microbiome over a 6-month period. We hypothesize that a single dose of azithromycin will result in a significant difference in the intestinal microbiome within the treatment group compared to the placebo group after a 6-month period within children ages 8 days-59 months. 2. . To determine the effect of a single dose of azithromycin for children aged 8 days-59 months on child growth over a 6-month period. We hypothesize that a single dose of azithromycin will increase child growth over a 6-month period in children aged 8 days-59 months. 3. . To determine the effect of a single dose of azithromycin for children aged 8 days to 59 months on the presence of macrolide genetic resistance determinants within the first two weeks post-treatment. The investigators hypothesize that a single dose of azithromycin will increase the presence of macrolide resistance determinants over a 2 week period in children aged 8 days to 59 months. The study will be conducted in Nouna Town in northwestern Burkina Faso.

Conditions

  • Child Growth
  • Diversity of Microbiome
  • Child Mortality
  • Resistance Bacterial

Interventions

  • AzithromycinDrug

    Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.

  • PlaceboDrug

    Oral suspension of placebo for azithromycin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intestinal Microbial DiversityTime frame: 6 months
  2. Macrolide ResistanceTime frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre de Recherche en Sante de Nouna

    Nouna, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.